Accompanying study of a multicenter phase II study to investigate the efficacy of systemic chemotherapy in patients with peritoneal washing cytology-positive potentially curable pancreatic cancer: Validation of quantifying peritoneal tumor DNA during systemic chemotherapy to monitor negative conversion of cancerous cytology and exploration for novel biomarkers of pancreatic cancer. (WALCURE DRIVE)

University of Toyama0 个研究点目标入组 180 人开始时间: 2023年9月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients must have histologically or cytologically confirmed adenocarcinoma.
•(2) Patients must be at least 20 years of age at the time of enrollment.
•(3) Patients must have a PS of 0-
•(4) Patients must not have received any prior therapy (radiation therapy, chemotherapy, immunotherapy, etc.) for the primary disease.
•(5) Consent to participate in the main study and this ancillary study has been obtained from the patient.

•(1) previous treatment (radiotherapy, chemotherapy, immunotherapy, etc.) has been given for the primary disease.
•(2) having undergone resection of the primary tumor.
•(3) having obvious infection or inflammation (e.g., fever over 38.0) at the time of study enrollment
•(4) having serious complications (requiring hospitalization), such as cardiac disease, intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, diabetes mellitus difficult to control, renal failure, or cirrhosis of the liver.
•(5) having a large amount of ascites or pleural effusion.
•(6) having a mental disorder that is being treated with antipsychotic drugs or is thought to require treatment, and is unable to understand the explanations given.
•(7) Unable to obtain effective informed consent.

发起方